Application Nr Approved Date Route Status External Links
ANDA212434 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Anastrozole Is An Aromatase Inhibitor Indicated For: Adjuvant Treatment Of Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer (1.1) First-Line Treatment Of Postmenopausal Women With Hormone Receptor-Positive Or Hormone Receptor Unknown Locally Advanced Or Metastatic Breast Cancer (1.2) Treatment Of Advanced Breast Cancer In Postmenopausal Women With Disease Progression Following Tamoxifen Therapy. Patients With Er-Negative Disease And Patients Who Did Not Respond To Previous Tamoxifen Therapy Rarely Responded To Anastrozole Tablets (1.3) 1.1 Adjuvant Treatment Anastrozole Tablets Are Indicated For Adjuvant Treatment Of Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer. 1.2 First-Line Treatment Anastrozole Tablets Are Indicated For The First-Line Treatment Of Postmenopausal Women With Hormone Receptor-Positive Or Hormone Receptor Unknown Locally Advanced Or Metastatic Breast Cancer. 1.3 Second-Line Treatment Anastrozole Tablets Are Indicated For The Treatment Of Advanced Breast Cancer In Postmenopausal Women With Disease Progression Following Tamoxifen Therapy. Patients With Er-Negative Disease And Patients Who Did Not Respond To Previous Tamoxifen Therapy Rarely Responded To Anastrozole Tablets.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Anastrozole ANASTROZOLE ZINC941

Comments